Immunotherapy Significantly Extends Survival in Patients with Rare Desmoplastic Melanoma
New research highlights how pembrolizumab immunotherapy significantly improves outcomes for patients with the rare and aggressive desmoplastic melanoma, offering a promising, less invasive treatment option.
Recent research led by UCLA investigators has demonstrated the promising potential of immunotherapy, specifically pembrolizumab, in treating advanced desmoplastic melanoma—a rare and highly aggressive type of skin cancer. This form of melanoma often develops in sun-damaged skin areas and features numerous genetic mutations, making it particularly challenging to treat.
The study, published in Nature Medicine, revealed that nearly 90% of patients experienced substantial tumor reduction or complete disappearance after treatment with pembrolizumab, an immune checkpoint inhibitor targeting PD-1. This drug works by helping the immune system recognize and attack cancer cells more effectively.
In a multicenter clinical trial called SWOG S1512, researchers focused on patients with unresectable metastases who received pembrolizumab every three weeks over two years. Results showed that 37% of these patients achieved complete tumor remission, and overall, 89% experienced tumor shrinkage or disappearance. Notably, responses were often rapid, with some patients showing tumor reduction within two months, and many maintaining remission long after stopping treatment.
The safety profile was manageable, although some older patients with additional health issues experienced side effects that led to early discontinuation. Despite this, the treatment's efficacy remained unaffected.
Senior author Dr. Antoni Ribas emphasized that these findings underscore the high response rates of desmoplastic melanoma to anti-PD-1 therapies, providing a less invasive and more targeted treatment option compared to surgery or radiation. This breakthrough offers hope to patients with this rare cancer subtype, narrowing the gap in treatment options.
The success of this immunotherapy approach marks a significant advancement, transforming prospects for patients with advanced desmoplastic melanoma and potentially other challenging melanoma variants. These findings advocate for the broader use of immune checkpoint inhibitors as a first-line treatment, especially given their low toxicity and high efficacy.
For more details, the full study can be accessed via Nature Medicine: link.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Lowering Dietary Serine Can Accelerate Skin Wound Healing by Influencing Hair Follicle Stem Cells
Research indicates that reducing dietary serine can prompt hair follicle stem cells to prioritize skin repair, leading to faster wound healing. Discover how nutrient levels influence stem cell behavior and tissue regeneration.
Research Indicates Pregnant Women Who Vape Are Exposed to Fewer Toxic Chemicals Than Smokers
A new study shows pregnant women who vape are exposed to fewer toxic chemicals compared to smokers, offering insights into safer quitting options during pregnancy.
Repurposing Diabetes Drugs to Enhance CAR T Cell Therapy for Bladder Cancer
Innovative research shows that diabetes medications like rosiglitazone can boost NECTIN4 expression, making bladder tumors more susceptible to CAR T cell therapy and improving treatment outcomes for resistant bladder cancer cases.
The Impact of Friendship on Neural Synchrony and Consumer Behavior
Research shows that friendships influence brain activity and behavior, promoting neural similarity and impacting consumer decisions. The study highlights the powerful role of social bonds in shaping neural and behavioral patterns.